"Sweet-P": Molecule for Targeting Human Glucocorticoid Receptor Beta in Cancer
- Detailed Technology Description
- Project ID: D2016-49 IP Status: PCT patent application filed Invention Description and Novelty: GRβ has been shown to increase growth and migration of cancer cells. Newly designed molecule suppresses GRβ to inhibit expression and migration of the cancer. Sweet-P is the only compound that has been shown to regulate GRβ. Applications: Treating GRβ-related diseases including bladder cancer, prostate cancer, lung cancer, leukemia, glioblastoma, liver cancer, breast cancer, lupus, and asthma, and methods for hindering migration of such cancers. Value proposition: • Compositions and methods for treatment of GRβ-related diseases; • Reduced to Practice: (1) Sweet-P blocks GRβ expression in lung and prostate cancer cells, and (2) Sweet-P blocks GRβ expression and migration of bladder cancer cells;• Also included is a kit for preparing a pharmaceutical composition;• No special method needed--Sweet-P can be synthesized through any method suitable for PNA synthesis.• Ready for commercialization and will not require an expensive and lengthy product development period.
- *Abstract
-
- *Principal Investigator
-
Name: Terry Hinds, Assistant Professor
Department: Physiology & Pharmacology
Name: Lucien McBeth, Graduate Student
Department: Physiology & Pharmacology
- Country/Region
- USA
For more information, please click Here
